HeartSciences Reports Modest Revenue Increase but Wider Net Loss Amid Operational Challenges

HeartSciences Inc. reported its financial results for the three months ended July 31, 2026, revealing a modest revenue increase to $2,100 from $1,900 in the same period last year. However, the company continues to face significant operational challenges, posting a net loss of $3.2 million, compared to a loss of $2.1 million in the prior year. The increase in losses is attributed to a substantial rise in selling, general, and administrative expenses, which surged by 132% to approximately $2.0 million, primarily due to higher professional fees related to a proposed merger and increased stock compensation expenses.

The company's total operating expenses for the quarter reached $2.9 million, a 57% increase from $1.9 million in the previous year. Research and development expenses decreased slightly to $906,629, down from $997,206, reflecting a shift in focus towards the MyoVista Insights™ platform, which is now the primary commercial focus of the company. HeartSciences has recorded an accumulated deficit of $88.4 million as of July 31, 2026, raising concerns about its ability to continue as a going concern.

Strategically, HeartSciences is pursuing a merger with Fortitude Mining Holdings, Inc., which was formalized in a merger agreement on June 23, 2026. This merger is contingent upon several closing conditions, including shareholder approval, and is expected to provide the necessary capital to support ongoing operations. In August 2026, the company raised approximately $1.0 million through a private placement of common stock, which will be used for operating expenses leading up to the merger.

Operationally, HeartSciences has made significant strides with its MyoVista Insights™ platform, which received an Epic Toolbox designation in March 2026, enhancing its integration within healthcare IT systems. The company has also launched an AI-ECG Algorithm Marketplace, allowing healthcare providers to access FDA-cleared cardiac AI tools. Despite these advancements, the company has not generated significant revenue from the MyoVista Insights™ platform, as it remains in the development stage.

Looking ahead, HeartSciences anticipates that it will require additional funding to support its operations and the continued development of its products. The company is exploring various financing options, including equity sales and strategic partnerships, but acknowledges the uncertainty surrounding its ability to secure such funding. The successful completion of the merger with Fortitude is seen as a critical step in addressing its financial challenges and achieving long-term growth.